Comparative Pharmacology
Head-to-head clinical analysis: APREPITANT versus EMETE CON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APREPITANT versus EMETE CON.
APREPITANT vs EMETE-CON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective high-affinity antagonist of the human substance P/neurokinin 1 (NK1) receptor, inhibiting emesis by blocking the binding of substance P in the central nervous system.
Antiemetic; dopaminergic antagonist at D2 receptors in the chemoreceptor trigger zone; also exhibits anticholinergic and antihistaminic properties.
125 mg orally once on day 1, then 80 mg orally once on days 2 and 3 of a 3-day chemotherapy regimen, given 1 hour before chemotherapy. Alternatively, a single 165 mg oral dose for prevention of postoperative nausea and vomiting.
12.5 mg intravenously over 30 seconds as a single dose; may repeat once after 1 hour if necessary.
None Documented
None Documented
Clinical Note
moderateAprepitant + Torasemide
"The metabolism of Torasemide can be increased when combined with Aprepitant."
Clinical Note
moderateAprepitant + Lornoxicam
"The metabolism of Lornoxicam can be increased when combined with Aprepitant."
Clinical Note
moderateAprepitant + Aceclofenac
"The metabolism of Aceclofenac can be increased when combined with Aprepitant."
Clinical Note
moderateAprepitant + Zaltoprofen
Terminal elimination half-life is approximately 9 to 13 hours in adults, allowing once-daily dosing. In pediatric patients, half-life may be shorter (about 5-6 hours).
Terminal elimination half-life is 8-12 hours in adults with normal renal and hepatic function; may extend to 15-20 hours in elderly or patients with hepatic impairment.
Aprepitant is eliminated primarily by metabolism; less than 5% is excreted unchanged in urine or feces. Approximately 50% of a dose is recovered in feces (mostly metabolites) and 10% in urine.
Primarily hepatic metabolism (CYP2D6, CYP3A4) with <5% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 60-70% of metabolites, with renal elimination of metabolites constituting 25-35%.
Category C
Category C
Antiemetic
Antiemetic
"The metabolism of Zaltoprofen can be increased when combined with Aprepitant."